Infosheet #5
For a Better QL of PLWHA!
(the VII CROI: Conference on
This conference is rated as the highest forum on scientific and clinical HIV and OI research.
The question when to start therapy is stil essential.
The Washington university clinical study shows that a delayed start results in
better virology outcomes and less opportunities for developing resistances.
There is no evidence on an improved immune system or HIV eradication by
starting early (abstr. #523).
Since the first combination fails in half of cases, it has to be chosen carefully
(R. Murphy, MD). Mixing the 16 ARV drugs theoretically gives 3360
combinations. Here are some of them.
E.g., ABC + AMP quickly suppresses HIV- 1 replication and is usually well
tolerated (#336).
NVR + ZDV + LMV is equal y effective in patients with low and even high VL
(>100.000) (#517).
nce daily Emtricitabine (FTC) + ddI + EFV in therapy- naïve patients after 24 weeks lowered VL<400, increased CD4 cel count and was well tolerated (#518).
Once daily EFV + NVP combination: it may be necessary to increase the EFV dose to 800 mg (#80).
Single pill combination of ABC + LMV + ZDV (twice daily) is biologically equal to its contents, has no dietary restrictions, is well- tolerated, easy to swallow and not disgusting (#98).
In order to evade cross- resistance – do not use combinations consisting of
al the 3 ARV classes (#80)!
Using NLF as the first PI causes less cross- resistances compared to other
PIs (dr. L. Prescott).
Discussion on drug holidays stil goes on. 5/8 of patients on HAART had to
restart therapy on the sixth week with their CD4 counts and CD4/CD8 ratios
lowered. In contrast, patients on Hydroxyurea + ddI (“PANDA” clinical study)
at the 8th week had a very smal VL increase at stable CD4 and CD8 counts.
This is the first study showing that STIs in chronical y infected patients are
feasible (#352).
60% of patients after 2 yrs on PIs are experiencing lipodistrophy.
Switching to another ARV class does not guarantee its disappearance -
lipodystrophy may not progress, though.
Some comparisons:Comparing PIs: AMP is less prone to cause lipodystrophy than IND.
d4T causes much more lipodystrophy cases than ZDV (#756).
14% of patients after 3 years on RTV + SQV are experiencing shrinkage in buttocks (D. W. Cameron).
While due to ARV combinations the virus is decreasing in bloodstream, it may
continue replicating in sperm.
33% of men on PIs are experiencing sexual dysfunction.
Abbott has a new salvage in its pipeline – an erectile medication Uprima.
Its effect is reached in 75% of men who sucked the pill for 20 min.
Compared to Viagra it has less of side effects.
Newly elaborated blood tests help to define the approximate timing of HIV
infection. These tests have proved that oral sex has been the cause of HIV
transmission in 8% of cases in San Francisco (abstr. #473).


Microsoft word - leukocel_package_insert.doc

LEUKOCEL Hydroxyurea capsules, USP 500 mg Each capsule contains Hydroxyurea Excipients DESCRIPTION LEUKOCEL (Hydroxyurea capsules, USP) is available for oral use as capsules providing 200 mg, 300 mg, and 400 mg Hydroxyurea. Inactive ingredients: citric acid, gelatin, lactose, magnesium stearate, sodium phosphate, titanium dioxide and capsule colorants: FD&C Blue

Microsoft word - 44d7940a-4ed9-282a42.doc

About Health TV with Jeanne Blake Prostate Cancer JEANNE BLAKE: Hi, I’m Jeanne Blake. Welcome to About Health. We have an important topic and a very special guest for this edition of About Health. The topic is the most common cancer in men over the age of 50. The cancer is prostate cancer, and our guest is a man you will recognize, who’s using his personal e

© 2010-2014 Pdf Medical Search